二肽基肽酶-4抑制剂致大疱性类天疱疮国内外文献分析

Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors:an analysis of domestic and foreign literature

目的:分析二肽基肽酶-4抑制剂致大疱性类天疱疮的发生规律及特点,为安全用药提供参考。方法:检索中国学术期刊全文数据库、维普中文科技期刊数据库、万方数据库和Pubmed数据库收载的二肽基肽酶-4抑制剂致大疱性类天疱疮文献并进行分析。结果:21例不良反应中,男性11例,女性10例,年龄60岁及以上患者20例(95.2%)。21例患者中,服用维格列汀者15例,服用西格列汀者3例,服用利拉列汀者3例。用药至发生大疱性类天疱疮的时间为1~37个月,平均时间8个月。结论:临床医师应了解二肽基肽酶-4抑制剂致大疱性类天疱疮的规律和特点,加强用药监测,以便及时发现和处理大疱性类天疱疮。

Objective： To analyze the general patterns and characteristics of bullous pemphigoid（ BP）induced by dipeptidyl peptidase-4（ DPP-4） inhibitors and to provide references for the clinical medication.Methods： BP of DPP-4 inhibitors reported in domestic and foreign academic journals via China National Knowledge Infrastructure（ CNKI）,Wanfang databases,VIP and Pubmed were collected and analyzed statistically. Results：Totally 21 cases of BP induced by DPP-4 inhibitors were collected,including 11 men and 10 women. Patients over the age of 60 years showed the higher incidence（ n = 20,95. 2%）. 21 cases of BP induced by DPP-4 inhibitors included vildagliptin（ n = 15）,sitagliptin（ n = 3） and linagliptine（ n = 3）. The average time was 8 months（ range 1 ~ 37 months）. Conclusion： Clinicians should be aware of the rules and characteristics of BP induced by DPP-4 inhibitors,and strengthen monitoring to detect and deal with DPP-4 inhibitors induced BP in time.